Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Interferons | 1 |
Biosimilar | 1 |
Top 5 Target | Count |
---|---|
IFNGR(Interferon gamma receptor) | 1 |
Target- |
Mechanism Immunosuppressants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL18R1 agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunosuppressants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date26 May 2023 |
Sponsor / Collaborator |
Start Date01 Jun 2021 |
Sponsor / Collaborator |
Start Date07 Aug 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Interferon gamma(Hayashibara Co., Ltd.) ( IFNGR ) | Skin Neoplasms More | Approved |
Iboctadekin ( IL18R1 ) | Melanoma More | Discontinued |
CS-560 | Hypersensitivity More | Discontinued |
CS-712 | Hypersensitivity More | Discontinued |
MHR-24 ( TNF ) | Lymphoma More | Pending |